Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-52555 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- GPSM2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: FQSNRMDDQR CCLQEKNCHT ASTTTSSTPP KMMLKTSSVP VVSPNTDEFL DLLASSQSRR LDDQRASFSN LPGLRLTQNS QSVLSHLMTN DNKEADEDFF D
- Concentration
- 0.2 mg/mL
Submitted references Truncated isoforms of GPSM2 containing the GoLoco motif region promote CD4(+) T-cell migration in SLE.
Esser RL, Brück C, Thiele J, Golumba-Nagy V, Meyer A, Steinbach-Knödgen E, Yan S, Tho Pesch C, Stahl D, Schiller J, Kofler DM
Lupus science & medicine 2022 Aug;9(1)
Lupus science & medicine 2022 Aug;9(1)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of GPSM2 in Lane 1: Marker (kDa) 230, 130, 95, 72, 56, 36, 28, 17, 11; Lane 2: Human cell line RT-4. Samples were probed using a GPSM2 Polyclonal Antibody (Product # PA5-52555).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of GPSM2 in human stomach tissue shows strong cytoplasmic positivity in glandular cells. Samples were probed using a GPSM2 Polyclonal Antibody (Product # PA5-52555).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 A truncated isoform of GPSM2 promotes CD4 + T-cell migration in SLE. (A) Representative example of western blot analysis of GPSM2 and the truncated 35 kDa GPSM2 isoform in CD4 + T cells from patients with SLE (SLE) and HCs. GPSM2 overexpressing lysate served as a positive ctrl (+); no protein served as a negative ctrl (-). (B) Comparison of GPSM2 expression in CD4 + cells from patients with SLE (n=10) and healthy individuals (n=9). (C) Expression of the truncated GPSM2 isoform in CD4 + cells from patients with SLE (n=10) and healthy individuals (n=9). (D) Schematic view of the experimental set-up of an in vitro T-cell migration assay. (E) Inhibition of the truncated GPSM2 isoform with blocking antibodies (block) or ctrl antibodies leads to decreased migration of CD4+ T cells from patients with SLE (n=9). Data are presented as mean+-SEM. Significance was calculated using unpaired (B, C) or paired (E) Student's t-test. ctrl, control; GPSM2, G-protein signalling modulator 2; HC, healthy control; n.s., not significant.
